S&P 500   3,971.27
DOW   32,394.25
QQQ   307.12
Walgreens Boots Alliance: Blue Chip, High-Yield Turnaround Story
Modern Day Options Trading For Beginners! (Ad)pixel
3 Small Financial Software Makers Showing Strong Chart Action
Roku And The 20% Rally That’s About To Start 
Modern Day Options Trading For Beginners! (Ad)pixel
Here’s Why Viking Therapeutics Rose Over 50% on Obesity Drug Data
Don't Be Fooled by These 3 Value Traps
Modern Day Options Trading For Beginners! (Ad)pixel
The Bottom Is In For McCormick & Company
Interactive Brokers: A Better Bet Than Schwab Post-SVB?
S&P 500   3,971.27
DOW   32,394.25
QQQ   307.12
Walgreens Boots Alliance: Blue Chip, High-Yield Turnaround Story
Modern Day Options Trading For Beginners! (Ad)pixel
3 Small Financial Software Makers Showing Strong Chart Action
Roku And The 20% Rally That’s About To Start 
Modern Day Options Trading For Beginners! (Ad)pixel
Here’s Why Viking Therapeutics Rose Over 50% on Obesity Drug Data
Don't Be Fooled by These 3 Value Traps
Modern Day Options Trading For Beginners! (Ad)pixel
The Bottom Is In For McCormick & Company
Interactive Brokers: A Better Bet Than Schwab Post-SVB?
S&P 500   3,971.27
DOW   32,394.25
QQQ   307.12
Walgreens Boots Alliance: Blue Chip, High-Yield Turnaround Story
Modern Day Options Trading For Beginners! (Ad)pixel
3 Small Financial Software Makers Showing Strong Chart Action
Roku And The 20% Rally That’s About To Start 
Modern Day Options Trading For Beginners! (Ad)pixel
Here’s Why Viking Therapeutics Rose Over 50% on Obesity Drug Data
Don't Be Fooled by These 3 Value Traps
Modern Day Options Trading For Beginners! (Ad)pixel
The Bottom Is In For McCormick & Company
Interactive Brokers: A Better Bet Than Schwab Post-SVB?
S&P 500   3,971.27
DOW   32,394.25
QQQ   307.12
Walgreens Boots Alliance: Blue Chip, High-Yield Turnaround Story
Modern Day Options Trading For Beginners! (Ad)pixel
3 Small Financial Software Makers Showing Strong Chart Action
Roku And The 20% Rally That’s About To Start 
Modern Day Options Trading For Beginners! (Ad)pixel
Here’s Why Viking Therapeutics Rose Over 50% on Obesity Drug Data
Don't Be Fooled by These 3 Value Traps
Modern Day Options Trading For Beginners! (Ad)pixel
The Bottom Is In For McCormick & Company
Interactive Brokers: A Better Bet Than Schwab Post-SVB?
NASDAQ:ALIM

Alimera Sciences - ALIM News Today

$1.95
+0.10 (+5.41%)
(As of 03/28/2023 12:00 AM ET)
Add
Compare
Today's Range
$1.80
$2.00
50-Day Range
$1.35
$2.94
52-Week Range
$1.30
$7.92
Volume
44,472 shs
Average Volume
21,254 shs
Market Capitalization
$13.65 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$6.75
Get Alimera Sciences News Delivered to You Automatically

Sign up to receive the latest news and ratings for ALIM and its competitors with MarketBeat's FREE daily newsletter.


ALIM Media Mentions By Week

ALIM Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

ALIM
News Sentiment

0.67

0.61

Average
Medical
News Sentiment

ALIM News Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

ALIM Articles
This Week

13

1

ALIM Articles
Average Week

SourceHeadline
finance.yahoo.com logoGlobal Non-Infectious Macular Edema Treatment Market to Reach $22.4 Billion by 2030
finance.yahoo.com - March 28 at 1:09 PM
marketwatch.com logo8-K: ALIMERA SCIENCES INC
marketwatch.com - March 28 at 1:09 PM
marketwatch.com logoAlimera Sciences Shares Rise 18% After Capital Restructuring
marketwatch.com - March 27 at 1:45 PM
finance.yahoo.com logoAlimera Improves Capital Structure, Strengthens Balance Sheet and Extends Term Loan Facility
finance.yahoo.com - March 27 at 1:45 PM
marketwatch.com logoProliferative Diabetic Retinopathy Market Share by 2031
marketwatch.com - March 26 at 12:37 PM
finance.yahoo.com logoAlimera Sciences to Report Fourth Quarter and Full Year 2022 Financial Results on Friday, March 31, 2023, and Provide Corporate Update
finance.yahoo.com - March 24 at 7:08 PM
finance.yahoo.com logoMacular Degeneration Treatment Global Market Report 2023
finance.yahoo.com - March 24 at 2:07 PM
marketwatch.com logoDiabetic Retinopathy Market Outlook to 2028
marketwatch.com - March 23 at 8:45 PM
MarketBeat logoStockNews.com Initiates Coverage on Alimera Sciences (NASDAQ:ALIM)
americanbankingnews.com - March 23 at 2:58 AM
marketwatch.com logoUveitis Treatment Market Size and Updated Report, Estimates & Forecast, By Application, segments 2023-2031
marketwatch.com - March 22 at 11:07 PM
marketwatch.com logoOphthalmology Biologics Market Share and Forecast till 2031
marketwatch.com - March 22 at 1:18 AM
marketwatch.com logoOcular Inflammation Treatment Market Growth and Forecast till 2028
marketwatch.com - March 17 at 8:29 AM
marketwatch.com logoOcular Inflammation Treatment Market To Observer Consistent Development All through Forecast Period 2023-2030
marketwatch.com - March 8 at 7:40 AM
marketwatch.com logo2023-2029 Retinal Vein Occlusion Market Size and Risks Factors Analysis | Survey Report by Absolute Reports
marketwatch.com - March 2 at 7:38 AM
finance.yahoo.com logoAlimera Appoints Roger Sawhney, M.D. to Its Board of Directors
finance.yahoo.com - February 27 at 10:42 AM
marketwatch.com logoAge-related Macular Degeneration Market Size 2023 with Pre COVID-19 and Post COVID-19 Market Scenario and Forecast till 2025
marketwatch.com - February 23 at 5:03 PM
markets.businessinsider.com logoH.C. Wainwright Reaffirms Their Buy Rating on Alimera (ALIM)
markets.businessinsider.com - February 23 at 9:11 AM
finance.yahoo.com logoAlimera Announces Submission of Marketing Authorization Application in Switzerland for ILUVIEN®
finance.yahoo.com - February 22 at 12:32 PM
marketwatch.com logoDiabetic Retinopathy Market Size Global Research Report, 2023 - 2028
marketwatch.com - February 21 at 4:15 AM
marketwatch.com logoGlobal Ocular Inflammation Treatment Market Technology advancement and Latest Research Report 2023-2028
marketwatch.com - February 20 at 7:17 AM
marketwatch.com logoIntravitreal (IVT) Injectables Market : Global Market Growth, New Trends, COVID-19 Impact and Forecast 2023 To 2028
marketwatch.com - January 31 at 10:19 AM
marketwatch.com logoDiabetic Retinopathy Market International Business Analysis, Development Outlook and Regional Strategies 2028
marketwatch.com - January 30 at 8:41 AM
marketwatch.com logoWet Age Related Macular Degeneration (AMD) Market Detailed Analysis of Current Industry Figures with Forecasts Regional Outlook 2028
marketwatch.com - January 13 at 6:09 PM
finance.yahoo.com logoAlimera Sciences Appoints Industry Veteran Russell L. Skibsted as Chief Financial Officer
finance.yahoo.com - January 9 at 1:05 PM
marketwatch.com logoDiabetic Retinopathy Market 2023 : Recent Developments, Industry Trends and Investigation Growth Rate, and Forecast to 2028
marketwatch.com - January 5 at 6:23 AM
finance.yahoo.com logoAlimera Sciences, Inc. (NASDAQ:ALIM) Q3 2022 Earnings Call Transcript
finance.yahoo.com - December 29 at 7:38 AM
msn.com logoLooking Into Alimera Sciences's Return On Capital Employed
msn.com - December 23 at 12:38 PM
marketwatch.com logoWet Age Related Macular Degeneration (AMD) Market Provides an In-Depth Insight of Trends and Landscape Outlook 2022-2028
marketwatch.com - December 12 at 7:12 AM
finance.yahoo.com logoAlimera Sciences Announces Agreement to Extend Amortization Date and Interest-Only Period on Loan Agreement
finance.yahoo.com - December 8 at 9:52 AM
finance.yahoo.com logoAlimera Highlights Abstracts Regarding Consensus Among US Retina Specialists and Reduced Retinal Thickness Variability Leading to Improved Visual Outcomes Following ILUVIEN® Administration
finance.yahoo.com - November 29 at 9:36 AM
finance.yahoo.com logo7 Stocks That Could Implode at Any Moment
finance.yahoo.com - November 25 at 1:59 AM
businesswire.com logoGlobal Diabetic Retinopathy Market Report to 2027 - Featuring Bayer, Alimera Sciences, Novartis and Pfizer Among Others - ResearchAndMarkets.com
businesswire.com - November 23 at 12:37 PM
finance.yahoo.com logoAlimera Sciences Third Quarter 2022 Earnings: Misses Expectations
finance.yahoo.com - November 16 at 6:49 AM
seekingalpha.com logoAlimera Sciences, Inc. (ALIM) Q3 2022 Earnings Call Transcript
seekingalpha.com - November 15 at 2:45 AM
finanznachrichten.de logoAlimera Sciences, Inc.: Alimera Sciences Announces Third Quarter 2022 Financial Results
finanznachrichten.de - November 14 at 11:35 AM
finance.yahoo.com logoAlimera Sciences Announces Third Quarter 2022 Financial Results
finance.yahoo.com - November 14 at 11:35 AM
finance.yahoo.com logoAlimera Sciences (ALIM) Reports Q3 Loss, Lags Revenue Estimates
finance.yahoo.com - November 14 at 11:35 AM
seekingalpha.com logoAlimera Sciences Q3 2022 Earnings Preview
seekingalpha.com - November 13 at 8:33 PM
marketwatch.com logoGlobal Diabetic Retinopathy Market Status and Trend 2022 Report by Competitive Landscape, Key Company Profiles, Types, Size and Forecast to 2028
marketwatch.com - November 7 at 10:32 AM
marketwatch.com logoOcular Drug Delivery Technology Market Size, Sales, CAGR And Competition Data from 2022 To 2028
marketwatch.com - November 5 at 4:56 AM
finance.yahoo.com logoAlimera Sciences to Report Third Quarter 2022 Financial Results on Monday, November 14, 2022, and Provide Corporate Update
finance.yahoo.com - November 2 at 9:23 AM
finance.yahoo.com logoAlimera Announces Reimbursement of Uveitis Indication Granted for ILUVIEN® in the Czech Republic
finance.yahoo.com - November 1 at 8:20 AM
msn.com logoIs Alimera Sciences (ALIM) Stock Outpacing Its Medical Peers This Year?
msn.com - October 20 at 11:47 AM
finance.yahoo.com logo10 Best Low Price Pharma Stocks To Buy Now
finance.yahoo.com - October 18 at 9:20 AM
finance.yahoo.com logoPaladin Phase 4 Study Confirms ILUVIEN® Patients' Reduced Need for Multiple Treatments
finance.yahoo.com - October 6 at 12:16 PM
finance.yahoo.com logoAlimera Announces Agreement with Jaeb Center for Health Research on Behalf of the DRCR Retina Network
finance.yahoo.com - September 23 at 10:25 AM
morningstar.com logoAlimera Sciences Inc ALIM Stock News
morningstar.com - September 21 at 12:25 AM
finance.yahoo.com logoAlimera Announces Reimbursement of Uveitis Indication Granted for ILUVIEN® in Ireland
finance.yahoo.com - September 20 at 7:25 PM
finance.yahoo.com logoAre Medical Stocks Lagging Alimera Sciences (ALIM) This Year?
finance.yahoo.com - September 19 at 1:09 PM
finance.yahoo.com logoAre Medical Stocks Lagging Alimera Sciences (ALIM) This Year?
finance.yahoo.com - September 19 at 1:09 PM
Get Alimera Sciences News Delivered to You Automatically

Sign up to receive the latest news and ratings for ALIM and its competitors with MarketBeat's FREE daily newsletter.

This page (NASDAQ:ALIM) was last updated on 3/29/2023 by MarketBeat.com Staff